The stock price of Natera, a clinical genetic testing company, has seen a 14% rise over the last twenty-one trading days, while it is up 30% year-to-date. The recent rise in the stock can be attributed to the company's launch of its Prospera heart transplant assessment test. Prospera test was...
The stock price of Natera, a clinical genetic testing company, has seen a 14% rise over the last twenty-one trading days, while it is up 30% year-to-date. The recent rise in the stock can be attributed to the company's launch of its Prospera heart transplant assessment test. Prospera test was...
Share this Article
Recommended